Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 6, Issue 2, 2010, Pages 371-381

  Wang, Qin ^a   Zhang, Liang ^a   Hu, Wei ^a   Hu, Zhan Hong ^a   Bei, Yong Yan ^a   Xu, Jing Yu ^a   Wang, Wen Juan ^a   Zhang, Xue Nong ^a   Zhang, Qiang ^b  

^a SOOCHOW UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Cellular uptake; Galactosylated chitosan; Hepatocyte targeted delivery; Nanoparticles; Norcantharidin

Indexed keywords

ANTI-TUMOR ACTIVITIES; AVERAGE PARTICLE SIZE; CELLULAR UPTAKE; CHITOSAN NANOPARTICLES; CLINICAL APPLICATION; CROSS-LINKAGE; ENTRAPMENT EFFICIENCY; GALACTOSYLATED CHITOSAN; HEPATOCARCINOMA; HEPATOCELLULAR CARCINOMA CELL; HEPATOCYTES; HEPATOMA CELLS; IN-VITRO; IN-VIVO; LIVER TUMORS; LOADING AMOUNT; PH SENSITIVE; TARGETED DELIVERY; TUMOR INHIBITION;

CELL CULTURE; CHITIN; NANOPARTICLES; TUMORS;

CHITOSAN;

CHITOSAN DERIVATIVE; GLYCOSYLATED CHITOSAN; NANOPARTICLE; NORCANTHARIDIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOMA CELL; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CROSS LINKING; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG PENETRATION; DRUG RELEASE; HEPATOBLASTOMA; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CARCINOMA; LIVER CELL; LOW DRUG DOSE; MOUSE; NANOENCAPSULATION; NANOFABRICATION; NONHUMAN; PARTICLE SIZE; PH; TARGET CELL; TUMOR MODEL;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHITOSAN; DRUG CARRIERS; GALACTOSE; LIVER NEOPLASMS; MICE; NANOPARTICLES;

MUS;

EID: 77949916194     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2009.07.006     Document Type: Article

References (47)

1. Liu X., Heng W.S., Paul, Li Q., and Chan L.W. Novel polymeric microspheres containing norcantharidin for chemoembolization. J Control Release 116 (2006) 35-41
2. Stewart S.G., Hill T.A., Gilbert J., Ackland S.P., Sakoef J.A., and Mccluskey A. Synthesis and biological evaluation of norcantharidin analogues: towards PP1 selectivity. Bioorg Med Chem 15 (2007) 7301-7310
3. Liu X.H., Blazsek I., Comisso M., Legras S., Marion S., Quittet P., et al. Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells. Eur J Cancer 31A (1995) 953-963
4. Wang G.S. Hydrolyze of norcantharidin and subtracting ethyl alleviate stimulation of renal system. Chin Pharm Bull 18 (1983) 18-20
5. Hill T.A., Stewart S.G., Ackland S.P., Gilbert J., Sauer B., Sakoef J.A., et al. Norcantharimides, synthesis and anticancer activity: synthesis of new norcantharidin analogues and their anticancer evaluation. Bioorg Med Chem 15 (2007) 6126-6134
6. Wang L.X., He H.B., Tang X., Shao R.Y., and Chen D.W. A less irritant norcantharidin lipid microspheres: formulation and drug distribution. Int J Pharm 323 (2006) 161-167
7. Zhang L., Sun X., and Zhang Z.R. An investigation on liver-targeting microemulsions of norcantharidin. Drug Deliv 12 (2005) 289-295
8. Zeng Q.B., and Sun M. Poly (lactide-co-glycolide) nanoparticles as carriers for norcantharidin. Mater Sci Eng C 29 (2009) 708-713
9. Chew J.L., Wolfowicz C.B., Mao H.Q., Leong K.W., and Chua K.Y. Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice. Vaccine 21 (2003) 2720-2729
10. Wu Y., Yang W.L., Wang C.C., Hu J.H., and Fu S.K. Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate. Int J Pharm 295 (2005) 235-245
11. Hudson S.M., and Jenkins D.W. Chitin and chitosan. In: Mark H.F. (Ed). EPST. 3rd ed Vol. 1 (2003), Wiley, New York 569-580
12. Morimoto M., Saimoto H., and Shigemasa Y. Control of functions of chitin and chitosan by chemical modifi{ligature}cations. Trends Glycosci Glycotechnol 14 (2002) 205-222
13. Morimoto M., Saimoto H., Usui H., Okamoto Y., Minami S., and Shigemasa Y. Biological activities of carbohydrate-branched chitosan derivatives. Biomacromolecules 2 (2001) 1133-1136
14. Li X.B., Tsushima Y., Morimoto M., Saimoto H., Okamoto Y., Minami S., et al. Biological activity of chitosan-sugar hybrids: specific interaction with lectin. Polym Adv Technol 11 (2000) 176-179
15. Donati I., Stredanska S., Silvestrini G., Vetere A., Marcon P., Marsich E., et al. The aggregation of pig articular chondrocyte and synthesis of extracellular matrix by a lactose-modified chitosan. Biomaterials 26 (2005) 987-998
16. Kato Y., Onishi H., and Machida Y. Lactosaminated and intact N-succinyl-chitosans as drug carriers in liver metastasis. Int J Pharm 226 (2001) 93-106
17. Kato Y., Onishi H., and Machida Y. Biological characteristic of lactosaminated N-succinyl-chitosan as a liver-specific drug carrier in mice. J Control Release 70 (2001) 295-307
18. Wang X.Q., Daia J.D., Zhen C., Tao Z., Xia G.M., Nagaic T., et al. Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive NPs for oral administration. Int J Pharm 97 (2004) 421-429
19. Banerjee T., Mitra S., Singh A.K., Sharma R.K., and Maitra A. Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. Int J Pharm 243 (2002) 93-105
20. Lu E., Franzblau S., Onyuksel H., and Popescu C. Preparation of aminoglycoside-loaded chitosan nanoparticles using dextran sulphate as a counterion. J Microencapsul 21 (2008) 1-9
21. Groman E.V., Enriquez P.M., Jung C., and Josephson L. Arabinogalactan for hepatic drug delivery. Bioconjug Chem 5 (1994) 547-556
22. Tozawa R., Ishibashi S., Osuga J., Yamamoto K., Yagyu H., Ohashi K., et al. Asialoglycoprotein receptor deficiency in mice lacking the major receptor subunit. J Biol Chem 276 (2001) 12624-12628
23. Bettinger T., Remy J.S., and Erbacher P. Size reduction of galactosylated PEI/DNA complexes improves lectin-mediated gene transfer into hepatocytes. Bioconjug Chem 10 (1999) 558-561
24. Dizhe E.B., Akifiev B.N., Missu B.V., Orlov S.V., Kidgotko O.V., Sukonina V.E., et al. Receptor-mediated transfer of DNA-galactosylated poly-l-lysine complexes into mammalian cells in vitro and in vivo. Biochemistry 66 (2001) 55-61
25. Murao A., Nishikawa M., Managit C., Wong J., Kawakami S., Yamashita F., et al. Targeting efficiency of galactosylated liposomes to hepatocytes in vivo: effect of lipid composition. Pharm Res 19 (2002) 1808-1814
26. Xu Z., Chen L., Gu W., Gao Y., Lin L., Zhang Z., et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 30 (2009) 226-232
27. Maitani Y., Kawano K., Yamada K., Nagai T., and Takayama K. Efficiency of liposomes surface-modified with soybean-derived sterylglucoside as a liver targeting carrier in HepG2 cells. J Control Release 75 (2001) 381-389
28. Gao S., Chen J., Xu X., Ding Z., Yang Y.H., Hua Z., et al. Galactosylated low molecular weight chitosan as DNA carrier for hepatocyte-targeting. Int J Pharm 255 (2003) 57-68
29. Chung T.W., Yang J., Akaike T., Cho K.Y., Nah J.W., Kim S.I., et al. Preparation of alginate/galactosylated chitosan scaffold for hepatocyte attachment. Biomaterials 23 (2002) 2827-2834
30. Calvo P., Remunan-Lopez C., Vila-Jato J.L., and Alonso M.J. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res 14 (1997) 1431-1436
31. Zhang W., Gong J.H., Zhang X.N., Liu Y., and Yang Z.Q. Multi-variable regression analysis applied to synchronously optimize preparation of nanoparticles. Chin Pharm J 43 (2008) 1162-1166
32. Huang M., Ma Z., Khor E., and Lim L.Y. Uptake of FITC-chitosan nanoparticles by A549 cells. Pharm Res 19 (2002) 1488-1494
33. Shimura N., Sogawa Y., Kawakita Y., Ikekita M., Yamazaki N., and Kojima S. Radioiodination of glycoprotein-conjugated liposomes by using the Bolton-Hunter reagent and biodistribution in tumor-bearing mice. Nucl Med Biol 29 (2002) 491-496
34. Xiong X.B., Huang Y., Lu W.L., Zhang X., Zhang H., Nagai T., et al. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release 107 (2005) 262-275
35. Tiyaboonchai W., and Limpeanchob N. Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles. Int J Pharm 329 (2007) 142-149
36. Wu Y., Yang W., Wang C., Hu J., and Fu S. Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate. Int J Pharm 295 (2005) 235-245
37. Torrado S., Cadorniga R., and Torrado J.J. Effect of drug release rate on bioavailability of different aspirin tablets. Int J Pharm 133 (1996) 65-70
38. Reza M.S., Quadir M.A., and Haider S.S. Comparative evaluation of plastic, hydrophobic and hydrophilic polymers as matrices for controlled-release drug delivery. J Pharm Pharmaceut Sci 6 (2003) 274-291
39. Ishii A., Hojo H., Nakahara Y., Ito Y., and Nakahara Y. Silyl linker-based approach to the solid-phase synthesis of Fmoc glycopeptides thioesters. Biosci Biotechnol Biochem 66 (2002) 225-232
40. Park I.K., Yang J., Jeong H.J., Bom H.S., Harada I., Akaike T., et al. Galactosylated chitosan as a synthetic extracellular matrix for hepatocytes attachment. Biomaterials 24 (2003) 2331-2337
41. Liang H.F., Yang T.F., Huang C.T., Chen M.C., and Sung H.W. Preparation of nanoparticles composed of poly (γ-glutamic acid)-poly (lactide) block copolymers and evaluation of their uptake by HepG2 cells. J Control Release 105 (2005) 213-225
42. Wu J., Liu L., Yen R.D., Catana A., Nantz M.H., and Zern M.A. Liposome-mediated extracellular superoxide dismutase gene delivery protects against acute liver injury in mice. Hepatology 40 (2004) 195-204
43. Meschini S., Molinari A., Calcabrini A., Citro G., and Arancia G. Intracellular localization of the antitumour drug adriamycin in living cultured cells: a confocal microscopy study. J Microsc 176 (1994) 204-210
44. Fiume L., Di Stefano G., Busi C., Incitti F., Rapicetta M., Farina C., et al. Coupling to lactosaminated poly-l-lysine reduces the toxic effects of ribavirin on red blood cells. J Hepatol 29 (1998) 1032-1033
45. Di Stefano G., Lanza M., Busi C., Barbieri L., and Fiume L. Conjugates of nucleoside analogs with lactosaminated human albumin to selectively increase the drug levels in liver blood: requirements for a regional chemotherapy. J Pharmacol Exp Ther 301 (2002) 638-642
46. Suzuki K., Tokoro A., Owaka Y., Suzuki S., and Suzuki M. Effect of N-acetyl chitooligosaccharides on activation of phagocytes. Microbiol Immunol 30 (1986) 777-787
47. Suzuki K., Mikami T., Okawa Y., Tokoro A., Suzuki S., and Suzuki M. Antitumor effect of hexa-N-acetylchitohexaose and chitohaxaose. Carbohydr. Res 151 (1986) 403-408